Shiseido Company, Limited (4911.T) fair value

ACCE thesis

Shiseido makes prestige skincare (Shiseido, Clé de Peau Beauté, Drunk Elephant and Dr. Dennis Gross in the US), along with fragrance and makeup sold through department stores, travel retail and e-commerce. The moat is a 77.3% gross margin, which is high for a beauty company and reflects brand pricing power in premium skincare that is hard to replicate quickly. Revenue growth of 10.5% is decent, but the 11.1% operating margin shows how much of that gross profit is still absorbed by marketing and retail costs, and the negative 3.1% ROE signals that reported earnings have not yet translated into shareholder returns. The stock trades at a forward P/E of 28.8, so the market is already pricing in a sustained margin recovery and a clean turnaround in the Chinese travel-retail and prestige channels. The question for the deeper dive is whether that operating margin can climb meaningfully from here, and whether the investment in Drunk Elephant and the cost base reset is producing the operating leverage the multiple assumes.